RNXT
RenovoRx, Inc. [RNXT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RNXT Stock Summary
Top 10 Correlated ETFs
RNXT
Top 10 Correlated Stocks
RNXT
In the News
RNXT Financial details
Company Rating
-
Market Cap
20.58M
Income
-10.23M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.62
Forward P/E
-
PEG
0.47
P/S
-
P/B
2459.41
P/C
-
P/FCF
-1.49
Quick Ratio
2.01
Current Ratio
2.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.71
EPS next Y
-
EPS next Q
-
EPS this Y
-8.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-11.11%
SMA50
-35.29%
SMA100
-22.81%
Inst Own
-
Inst Trans
-
ROA
-258%
ROE
-342%
ROC
-6.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.531-3.29
52W High
-
52W Low
-
RSI
50.57
Rel Volume
0.73
Avg Volume
51.02K
Volume
37.23K
Perf Week
14.46%
Perf Month
-0.73%
Perf Quarter
2.15%
Perf Half Y
-4.51%
-
-
-
-
Beta
1.041
-
-
Volatility
0.1%, 0.08%
Prev Close
-6.86%
Price
0.95
Change
-7.77%
Company Profile
- Volume Average 51.02K
- Market Capitalization 20.58M
- Employee 8
- CEO Mr. Shaun R. Bagai
- Headquarters Los Altos,CA,US
- IPO Date 2021-08-26
-
Website
https://renovorx.com 
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
